Biogen Inc. Announces First Quarter Financial Results for 2025

Biogen Inc. has reported a notable increase in its first-quarter revenue for the fiscal year 2025, reaching $2.4 billion, which marks a 6% growth compared to the same period in 2024. This achievement underscores the company's robust performance and strategic direction.

Financial Highlights and Challenges

Despite the revenue uptick, the company faced challenges with its GAAP diluted earnings per share, which decreased year over year to $1.64. Additionally, the net income attributable to Biogen Inc. for the quarter ending March 31 was reported at $240.5 million.

CEO's Perspective on Growth and Strategy

"Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter derived from important medicines outside of our MS business," stated CEO Christopher Viehbacher.